$CNPOF $RIV.V Invests Additional US $10 Million in TerrAscend

TORONTO, Oct. 2, 2019  – Canopy Rivers Inc. (“Canopy Rivers“) (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, has completed a US $10 million investment (the “Investment“) in TerrAscend Canada Inc. (“TerrAscend Canada“), a subsidiary of its portfolio company TerrAscend Corp. (“TerrAscend“) (CSE: TER, OTCQX: TRSSF). The investment includes the purchase of 13,243 units, with each unit consisting of: (i) one unsecured convertible debenture of TerrAscend Canada with a principal amount of CA $1,000 (the “Debentures“), and (ii) 25.2 common share purchase warrants of TerrAscend exercisable until October 2, 2024 (the “Warrants“).

TerrAscend is the first and only cannabis company with sales in Canada, the U.S., and Europe. TerrAscend’s international cannabis portfolio includes a robust research and development platform, domestic and international cultivation, processing, and distribution facilities, and a portfolio of medical and adult-use branded cannabis products, and is one of a select group of industry operators to have been recognized with a European Good Manufacturing Practices (“EU GMP”) certification. TerrAscend is also an active participant in the Canopy Rivers ecosystem, with significant agreements in place with Canopy Rivers portfolio companies PharmHouse Inc. and James E. Wagner Cultivation Corporation.

“We think TerrAscend is uniquely positioned to meet the evolving consumer demands in the three largest cannabis markets worldwide,” said Narbe Alexandrian, President & CEO of Canopy Rivers. “We strongly believe in TerrAscend’s ability to execute on its global strategy, market a diversified brand portfolio, and build on its recent acquisitions, and this additional investment is an affirmation of that belief.”

“We are privileged to have the continued confidence and support of Canopy Rivers, one of the preeminent investment firms specializing in cannabis,” said Michael Nashat, CEO of TerrAscend. “This growth capital enables us to accelerate our organic and acquisition-driven investments in our key markets across the globe, as we execute our strategic vision of being a truly global cannabinoid company.”

Canopy Rivers, along with Canopy Growth Corporation, first invested in TerrAscend in November 2017. In October 2018, both parties restructured their investment in TerrAscend. This restructuring enabled TerrAscend to pursue strategic international transactions in the cannabis space while ensuring all parties remained compliant with industry and securities regulations.

Transaction Overview

The Debentures will bear interest at a rate of 6.0% per annum and will mature on October 2, 2024. Each Debenture will be convertible into common shares or exchangeable shares in the capital of TerrAscend at the option of Canopy Rivers or upon the occurrence of certain events at a conversion price of CA $5.95, a 10% premium to the 5-day VWAP ended September 30, 2019. TerrAscend fully and unconditionally guarantees TerrAscend Canada’s obligations under the Debentures, such guarantee to be enforceable by the payment of the equivalent value in exchangeable shares of TerrAscend or, upon the occurrence of certain events, in common shares or in cash.

Each Warrant will entitle Canopy Rivers to acquire one common share of TerrAscend, at an exercise price of CA $6.49, a 20% premium to the 5-day VWAP ended September 30, 2019, and such Warrants will be exercisable following changes in U.S. federal laws regarding the cultivation, distribution or possession of marijuana, the compliance of TerrAscend with such laws, and the approval of the securities exchanges upon which Canopy Rivers is listed.

Net proceeds from the Investment will be used by TerrAscend Canada for general corporate purposes and will not be used in connection with cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States.

About Canopy Rivers

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the terms of the Investment; the conversion of the Debentures into common shares or exchangeable shares of TerrAscend; Canopy Rivers’ right to acquire common shares of TerrAscend pursuant to the Warrants; the use of proceeds from the Investment; management’s belief that TerrAscend is uniquely positioned to meet evolving consumer demands in the three largest cannabis markets worldwide; management’s belief in TerrAscend’s ability to execute on its global strategy, market a diversified brand portfolio, and build on its recent acquisitions; the expectation that the Investment will enable TerrAscend to accelerate its investments in key markets; and expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; the ability of Canopy Rivers to exercise the Warrants in order to acquire common shares of TerrAscend; changes in the use of proceeds from the Investment; TerrAscend’s ability to complete and integrate acquisitions and other global strategies and to market a diversified brand portfolio; changes in consumer demands and TerrAscend’s ability to meet such demands; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

$YGYI Timing for Regular Monthly Dividend for Sept. 2019 Series “D” Cumulative

SAN DIEGO, Oct. 1, 2019 — Youngevity International, Inc. (NASDAQ: YGYI), a leading multi-channel lifestyle company, today announced the timing for the payment of its declared regular monthly dividend of $0.203125 per share of its 9.75% Series D Cumulative Redeemable Perpetual Preferred Stock (NASDAQ:YGYIP) for September 2019. The dividend will be payable on October 15, 2019 to holders of record as of September 30, 2019. The dividend will be paid in cash.

About Youngevity International, Inc.

Youngevity International, Inc. ( NASDAQ : YGYI ), is a multi-channel lifestyle company operating in 3 distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise.  The Company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity, YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit YGYI.com. Be sure to like us on Facebook and follow us on Twitter

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions.  These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contacts:

Youngevity International, Inc.
Dave Briskie
President and Chief Financial Officer
1 800 982 3189 X6500

Investor Relations
YGYI Investor Relations
800.504.8650
investors@ygyi.com

$TGODF Hosts Industry Analysts at Hamilton and Valleyfield Facilities

October 1, 2019

• The company hosted site visits with analysts from Canada and the United States
• TGOD is strategically creating a sustainable footing in Canada, Europe, the Caribbean and Latin America
• The company is dedicated to making life better, both locally and globally

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) uses certified organic, craft growing practices to cultivate high-quality organic medical cannabis. The company consistently holds to the highest levels of excellence as it strives to become the global leader in organic cannabis solutions. Through innovative tech and low-cost power solutions, TGOD is able to provide cost-efficient premium cannabis.

On September 19-20, the company hosted site visits for approximately 25 analysts at its Hamilton and Valleyfield facilities (http://cnw.fm/aC9Ly). This marked the first time that TGOD has shared to this extent its Canadian flower production ramp-up, the unveiling of the cannabis 2.0 portfolio and a sampling of noninfused beverage formulations, which were well received. Management also provided an update on the phased facility’s construction completion.

Along with management, TGOD’s growing operations team introduced analysts from Canada and the United States to the company’s cultivation differentiator, proprietary technology and horticultural practices. Analysts walked the grounds of the combined 1,476,000 sq. ft. purpose-built facilities and received updates on the completion of Hamilton’s hybrid greenhouse and Valleyfield’s anticipated first harvest. Total annual production capacity at Hamilton is now 17,500 kilograms; Valleyfield will have approximately 65,000 kilograms of annual run rate capacity turning on in the fourth quarter of 2019 (http://cnw.fm/Jkn4a).

“We are doing something no other producer has done before, growing premium certified organic cannabis at scale,” TGOD CEO Brian Athaide stated in a news release (http://cnw.fm/Z6NlA). “By leveraging our proprietary growing methods, purpose-built facilities and industry-leading horticultural team, we are creating a wide economic moat within the premium organic segment… We are extremely proud to showcase the hard work that went into designing and building these state-of-the-art facilities as well as our cannabis 2.0 portfolio.”

TGOD is strategically creating a sustainable footing in Canada, Europe, the Caribbean and Latin America. The company’s approach is unique and includes operating cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. Experience gained from previous business ventures has led TGOD to focus on:

• Cultivating organically and at scale;
• Ensuring logistical and infrastructure controls;
• Utilizing strategic partnerships with experts in their fields; and
• Growing its world class CPG senior management team.

TGOD is committed to making life better and nurturing a community that respects a sustainable way of life. This philosophy is at the heart of everything the company does, both on-site and off. Although the company has eyes on esetablishing itself as the global leader in certified organic cannabis, TGOD has not forgotten its roots. The company’s goal is to also create a positive economic impact in local towns and communities across Canada. Following this mission, TGOD produces more than just cannabis. Community Farm, a plot of land within the Hamilton Ancaster Facility Grounds, grows organic food and provides it to local food-donation programs. More than 2,000 pounds of high-quality food has been given to Hamilton food-share programs, a further example that The Green Organic Dutchman is 100 percent committed to ‘Making Life Better’, both at home and around the world.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://cnw.fm/TGODF

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$PBIO Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow

Data from Analysis of Cancer Tissue Proteins Generated from Novel Workflow Could Lead to Improvement in the Clinical Management of Gynecological Cancers

SOUTH EASTON, Mass., Oct. 01, 2019 — via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of a new, innovative workflow for the analysis of proteins from cancer biopsy samples.  This workflow was presented in a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. The mission of the IGCS is to improve the care and outcomes for women with gynecologic cancer worldwide through education, training and public awareness.

According to Dr. Larry Maxwell, MD, gynecologic oncologist and Chair of OB-GYN at Inova Fairfax Hospital, “the conventional use of chemotherapy in ovarian cancer treatment is being rapidly replaced by biologic therapeutics that target the cancer (the “seed”) and also the micro-environment (the “soil”) in which it grows.  Being able to collect small tissue specimens and characterize them across multiple genomic and proteomic platforms will enable us to markedly enhance our ability to develop companion diagnostics and prognostics as well as identify targets for future therapeutic strategies.  Technology provided by Pressure BioSciences has become an essential requirement for our novel workflow in meeting our goals.”

Gynecologic malignancies include ovarian, uterine, and cervical cancers.  Together they are responsible for approximately 35,000 deaths annually in the United States with ovarian cancer ranking fifth in cancer deaths among women (Aurora Healthcare and the Centers for Disease Control and Prevention). According to Acumen Research and Consulting (2018), the global ovarian cancer diagnostics market alone is forecasted to grow at a CAGR around 5.9% over the forecast time frame and reach around US $1.8 billion by 2026.  New, improved methods to detect these cancers are vitally needed to support the design and development of better treatments through enhanced precision medicine. The IGCS is committed to addressing this critical issue.

Dr. Thomas Conrads, a nationally acclaimed protein chemist, is the Senior Director of Women’s Health Research at the Inova Women’s Hospital.  Dr. Conrads’ group was invited to present their innovative workflow for analyzing cancer tissue proteins at the IGCS meeting. The presentation titled Interim Analysis of Ovarian Cancer by the US National Cancer MOONSHOT’S Tri-Federal (DOD/NCI/VA) Applied Proteogenomic Organizational Learning and Outcomes (APOLLO) Research Network, was made by Dr. Maxwell.  Data demonstrated the feasibility of proteogenomic characterization of known-patient tumors for specimen preparation in support of large-scale analyses in the U.S. Cancer Moonshot’s APOLLO program. This program focuses on genetic sequencing and proteomic analysis of tumors in order to develop clinically actionable molecular panels for precision medicine and personalized health.

The novel workflow developed by Dr. Conrads and his colleagues integrates the Leica Microsystems’ laser microdissection (LMD) platform and PBI’s PCT platform, enabling micro-scale quantitative proteomics and phosphoproteomics on a ThermoFisher Scientific mass spectrometry (MS) instrument.  LMD is a state-of-the-art method for precise excision of cells from biopsy tissues at microscopic scale by a laser.  Excised cells are delivered directly into PBI’s MicroTubes for critical sample preparation, including rapid and efficient high-quality cellular protein release.  Proteins are then analyzed by mass spectrometry (MS), the global method-of-choice for high throughput and comprehensive protein analysis.

Dr. Conrads commented: “We are very pleased to have been invited to present the results of our work in gynecologic cancer research in a plenary session at this important international meeting. The novel workflow developed by our group integrates and operationalizes state-of-the art techniques: laser microdissection (LMD), pressure cycling technology (PCT), and mass spectrometry (MS) to improve our understanding of the complex tissue microenvironment and, in this case, to enable identification of biomarkers associated with women’s cancers.  We believe that the insights we gain from applying this novel workflow will result in significant improvements in the clinical management of gynecologic cancer.”

Dr. Nate Lawrence, Senior Consultant to PBI, said, “Precision medicine promises a paradigm shift in the diagnosis and treatment of disease.  This shift is highly dependent on the generation and evaluation of high-quality data generated during comprehensive analyses of each patient’s tumor samples. Although critical to precision medicine the generation of such data from biopsy samples has been difficult to date, as it requires the integration of multiple and varied laboratory processes, including tissue extraction, critical sample processing, and analysis. The innovative workflow developed by Dr. Conrads and his colleagues combines the precision of Leica Microsystems’ state-of-the-art LMD system on the frontend with the superior analytical capabilities of Thermo Scientific’s mass spectrometer on the backend.  In the middle, integral to connecting these two superb instrument systems, is the speed, robustness, reproducibility, and versatility of PBI’s PCT Barocycler system.”

Mr. Richard T. Schumacher, President and CEO of PBI, concluded: “We were delighted to see PBI’s Barocycler system featured in its pivotal position in this important new tumor processing workflow that Dr. Conrads and his colleagues have presented: the critical enabling step after LMD excision and before MS analysis.  Based on results to date, we believe that the number of laboratories worldwide performing laser microdissection followed by mass spectrometric analyses will increase at a steady but significant rate, that our Barocycler system will remain a critical part of this workflow, and that the adoption of this novel new workflow should result in a measurable increase in Barocycler sales over the coming months and years.”

About Inova
Inova is Northern Virginia’s leading nonprofit healthcare provider, recognized in 2019 by U.S. News & World Report which named the Inova Fairfax Medical Campus the #1 hospital in the Washington, DC, region with four of Inova’s five hospitals receiving five-star rankings from the Centers for Medicare and Medicaid Services.  Our mission is to provide world-class healthcare – every time, every touch – to each person in every community we have the privilege to serve.  Inova’s 18,000 team members serve more than 2 million individuals annually through an integrated network of hospitals, primary and specialty care practices, emergency and urgent care centers, outpatient services and destination institutes.  Inova is home to Northern Virginia’s only Level 1 Trauma Center and Level 4 Neonatal Intensive Care Unit.  Its hospitals have a total of 1,800 licensed beds.

Four of Inova’s five hospitals have received five-star rankings from the Centers for Medicare and Medicaid Services (CMS) and three are ranked in the top 10 in the region by US News and World Report; they are the only hospitals in the Washington, DC region to have earned the highest rating from CMS and straight “A” grades from Leapfrog Hospital Safety Grades. Inova connects researchers, clinicians and empowered consumers to improve patient care, enhance prevention and encourage wellness. More information and statistics about Inova can be found at inova.org.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Investor Contacts:
Richard T. Schumacher, President and CEO, (508) 230-1828 (T)
Nathan P. Lawrence, Ph.D., Senior Consultant, (508) 230-1829 (F)

$GGBXF Cannabis Expo in West Michigan Set to Educate Consumers and Businesses

October 1, 2019

The WMCE (West Michigan Cannabis Expo) will be all things marijuana. It is a two-day event, that will be held at DeltaPlex Arena in Grand Rapids. The event which will be having 60 booths plus is a perfect opportunity for consumers, businesses and other professionals in the cannabis industry to showcase their products and services. It is also an avenue for learning more about the marijuana industry.

The expo also aims to help businesses to develop new leads, strengthen their relationship with their clients and customers, and market their organization.

Some of those who will be in attendance include a hemp product company, cannabinoids retailers, equipment retailers, consumers and growers, as well as legal and accounting professionals.

The WMCE commences on Saturday 5^th October. The event opens at 10 a.m and will end at 5 p.m. October 6^th is the last day of the expo, and it will be open from 10 a.m to 4 p.m at the DeltaPlex Arena.

DeltaPlex director of events development, Chris Hudson says that business-oriented people expected to attend the event are about 60 percent while the remaining 40 percent comprises of cannabis consumers and people who would like to learn more about the industry.

In November 2018, Michigan legalized marijuana for personal use while medical marijuana was legalized in 2008. The legislation governing recreational marijuana provides that you must be 21 years or older to purchase, use or cultivate marijuana.

According to Hudson, the WMCE was organised after significant growth was observed that in the sector since the legalization of recreational marijuana as people from other states came to Michigan to get their fix. More so, businesses and individuals seeking to join the industry have many questions, and the Expo would help answer and educate them on how to join the marijuana industry. The expo would also help them gain resources such as machines required to make and extract marijuana products.

During the expo, there will be cannabis-cooking demonstrations, seminars on marijuana licensing and banking with cannabis, cannabis medicines displays, and extracts.

The cost of a ticket is $15 for one day, but if you want to attend both days, you will have to pay $25. There is also an upgraded ticket that costs $50, which allows you to participate in a mixer on Saturday at 5.30 p.m. The mixer is for adults who are 21 years and above.

THC products are not allowed into the expo because the state will accept recreational business applications in November.

Analysts are of the view that industry players like Grapefruit Boulevard Investments Inc. (OTCQB: IGNG) and Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) are happy that such events are being organized to bring marijuana into the mainstream.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$POAI Subsidiary Participates in UK 100,000 Genomes Project

October 1, 2019